{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T08:51:39Z","timestamp":1789462299100,"version":"build-2803163510"},"reference-count":15,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,7,28]],"date-time":"2023-07-28T00:00:00Z","timestamp":1690502400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1016\/j.ejca.2023.113259","type":"journal-article","created":{"date-parts":[[2023,7,27]],"date-time":"2023-07-27T21:26:08Z","timestamp":1690493168000},"page":"113259","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["Pooled Safety Analysis of Single-Agent Lurbinectedin in Patients With Advanced Solid Tumours"],"prefix":"10.1016","volume":"192","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2043-2244","authenticated-orcid":false,"given":"Alexandra","family":"Leary","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Oaknin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Manuel","family":"Trigo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor","family":"Moreno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Pierre","family":"Delord","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Boni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Bra\u00f1a","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristian","family":"Fern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Kahatt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Nieto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1631-5707","authenticated-orcid":false,"given":"Martin","family":"Cullell-Young","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Zeaiter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6064-6837","authenticated-orcid":false,"given":"Vivek","family":"Subbiah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2023.113259_bib1","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1021\/ol0062502","article-title":"Synthesis of ecteinascidin ET-743 and phthalascidin Pt-650 from cyanosafracin B","volume":"2","author":"Cuevas","year":"2000","journal-title":"Org Lett"},{"key":"10.1016\/j.ejca.2023.113259_bib2","doi-asserted-by":"crossref","first-page":"8248","DOI":"10.1093\/nar\/gkr512","article-title":"Temperature-induced melting of double-stranded DNA in the absence and presence of covalently bonded antitumour drugs: insight from molecular dynamics simulations","volume":"39","author":"Bueren-Calabuig","year":"2011","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.ejca.2023.113259_bib3","doi-asserted-by":"crossref","first-page":"6657","DOI":"10.1158\/0008-5472.CAN-16-0568","article-title":"Lurbinectedin inactivates the Ewing sarcoma oncoprotein EWS-FLI1 by redistributing It within the nucleus","volume":"76","author":"Harlow","year":"2016","journal-title":"Cancer Res"},{"key":"10.1016\/j.ejca.2023.113259_bib4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1158\/1535-7163.MCT-16-0172","article-title":"Lurbinectedin specifically triggers the degradation of phosphorylated RNA polymerase II and the formation of DNA breaks in cancer cells","volume":"15","author":"Santamaria Nunez","year":"2016","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.ejca.2023.113259_bib5","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1111\/j.1476-5381.2010.00945.x","article-title":"PM01183, a new DNA minor groove covalent binder with potent in vitro and in vivo anti-tumour activity","volume":"161","author":"Leal","year":"2010","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.ejca.2023.113259_bib6","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/S1470-2045(20)30068-1","article-title":"Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial","volume":"21","author":"Trigo","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2023.113259_bib7","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2015.33.15_suppl.tps2604","article-title":"A multicenter phase II basket clinical trial of lurbinectedin (PM01183) in selected advanced solid tumors","volume":"33","author":"Provencio Pulla","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2023.113259_bib8","doi-asserted-by":"crossref","first-page":"2378","DOI":"10.1158\/1078-0432.CCR-20-3901","article-title":"FDA approval summary: lurbinectedin for the treatment of metastatic small cell lung cancer","volume":"27","author":"Singh","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2023.113259_bib9","doi-asserted-by":"crossref","first-page":"2762","DOI":"10.1158\/1078-0432.CCR-22-0696","article-title":"Antitumor activity of lurbinectedin, a selective inhibitor of oncogene transcription, in patients with relapsed Ewing Sarcoma: results of a basket phase II study","volume":"28","author":"Subbiah","year":"2022","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2023.113259_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2022.100571","article-title":"Lurbinectedin, a selective inhibitor of oncogenic transcription, in patients with pretreated germline BRCA1\/2 metastatic breast cancer: results from a phase II basket study","volume":"7","author":"Boni","year":"2022","journal-title":"ESMO Open"},{"key":"10.1016\/j.ejca.2023.113259_bib11","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.ygyno.2021.08.032","article-title":"Lurbinectedin versus pegylated liposomal doxorubicin or topotecan in patients with platinum-resistant ovarian cancer: a multicenter, randomized, controlled, open-label phase 3 study (CORAIL)","volume":"163","author":"Gaillard","year":"2021","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ejca.2023.113259_bib12","year":"2009","journal-title":"Common terminology criteria for adverse events v. 4. 0 (CTCAE)"},{"key":"10.1016\/j.ejca.2023.113259_bib13","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1002\/pds.1211","article-title":"Hy's law: predicting serious hepatotoxicity","volume":"15","author":"Temple","year":"2006","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.ejca.2023.113259_bib14","volume":"94304","year":"2022"},{"key":"10.1016\/j.ejca.2023.113259_bib15","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.ejca.2022.06.024","article-title":"Lurbinectedin in patients with pretreated neuroendocrine tumours: results from a phase II basket study","volume":"172","author":"Longo-Munoz","year":"2022","journal-title":"Eur J Cancer"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804923003611?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804923003611?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:41:56Z","timestamp":1760733716000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804923003611"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":15,"alternative-id":["S0959804923003611"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2023.113259","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pooled Safety Analysis of Single-Agent Lurbinectedin in Patients With Advanced Solid Tumours","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2023.113259","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"113259"}}